Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% Clindamycin as Clindamycin Phosphate and 5% Benzoyl Peroxide) Once Daily Gel Compared With Clindamycin Phosphate Gel (1% Clindamycin as Clindamycin Phosphate) Twice Daily in the Treatment of Mild to Moderate Acne Vulgaris.
Brief Summary: This is a multicentre, randomized, assessor-blind, comparator-controlled evaluation of the efficacy, safety, and tolerability of Duac™Once Daily Gel and clindamycin phosphate gel in the topical treatment of mild to moderate facial acne vulgaris. A total of 1020 subjects will be enrolled, 510 per study arm. The subjects will be males and females between 12 and 45 years of age, inclusive, at the time of consent, who have mild to moderate facial acne vulgaris.

Subjects will use Duac™Once Daily Gel (once daily in the evening) or clindamycin phosphate gel twice daily (once in the morning and once in the evening) for 12 weeks. The subjects will be evaluated for change in lesion counts, investigator's static global assessment (ISGA), subject's global assessment (SGA), local tolerability and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit.


Options:
A: Arm Label: Duac® fixed dose combination gel; Type: EXPERIMENTAL; Interventions: Drug: Duac® fixed dose combination gel | Arm Label: Combination therapy: ADA 0.1% gel + CLDM 1% gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADA 0.1% gel, Drug: CLDM 1% gel | Intervention Type: DRUG; Name: Duac® fixed dose combination gel; Assigned to Arm(s): Duac® fixed dose combination gel | Intervention Type: DRUG; Name: ADA 0.1% gel; Assigned to Arm(s): Combination therapy: ADA 0.1% gel + CLDM 1% gel | Intervention Type: DRUG; Name: CLDM 1% gel; Assigned to Arm(s): Combination therapy: ADA 0.1% gel + CLDM 1% gel
B: Arm Label: Duac™Once Daily Gel; Type: EXPERIMENTAL; Interventions: Drug: 1% clindamycin phosphate gel | Arm Label: 1% clindamycin phosphate gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duac™Once Daily Gel | Intervention Type: DRUG; Name: Duac™Once Daily Gel; Assigned to Arm(s): 1% clindamycin phosphate gel | Intervention Type: DRUG; Name: 1% clindamycin phosphate gel; Assigned to Arm(s): Duac™Once Daily Gel
C: Arm Label: Part 1: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 1: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Arm Label: Part 2: ABPO Forte Gel; Type: EXPERIMENTAL; Interventions: Drug: ABPO Forte Gel | Arm Label: Part 2: ABPO Forte Vehicle Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: ABPO Forte Gel; Assigned to Arm(s): Part 1: ABPO Forte Gel, Part 2: ABPO Forte Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Part 1: ABPO Forte Vehicle Gel, Part 2: ABPO Forte Vehicle Gel
D: Arm Label: Adapalene/Benzoyl Peroxide Gel; Type: EXPERIMENTAL; Interventions: Drug: Adapalene/Benzoyl Peroxide | Arm Label: Adapalene Gel, 0.1%; Type: EXPERIMENTAL; Interventions: Drug: Adapalene Gel, 0.1% | Arm Label: Benzoyl Peroxide Gel 2.5%; Type: EXPERIMENTAL; Interventions: Drug: Benzoyl Peroxide Gel 2.5% | Arm Label: Gel Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Gel Vehicle | Intervention Type: DRUG; Name: Adapalene/Benzoyl Peroxide; Assigned to Arm(s): Adapalene/Benzoyl Peroxide Gel | Intervention Type: DRUG; Name: Adapalene Gel, 0.1%; Assigned to Arm(s): Adapalene Gel, 0.1% | Intervention Type: DRUG; Name: Benzoyl Peroxide Gel 2.5%; Assigned to Arm(s): Benzoyl Peroxide Gel 2.5% | Intervention Type: DRUG; Name: Gel Vehicle; Assigned to Arm(s): Gel Vehicle

Answer: B